Relay Therapeutics Hopes ‘Safety First’ Approach Will Pay Off For Targeted Breast Cancer Drug

Share Price Tanks After Virtually No Response To Therapy

 
• By Andrew McConaghie
  
Orlando convention center
Relay Therapeutics presented its data at the AACR congress in Orlando, Florida. • Source: Shutterstock

More from Clinical Trials

More from R&D